Natera to Present Clinical and Economic Utility of Signatera at ESMO GI, Highlights Innovations in MRD
Natera, Inc. (
NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced new data that will be presented at the 2025 European Society for Medical Oncology GI Congress (ESMO GI) in Barcelona, Spain. These presentations reinforce the strong clinical and economic utility of Signatera™ monitoring across colon and rectal cancers (CRC), as well as new clinical validation data on its tissue-free MRD assay.
Q1 Immuno-Oncology Earnings Review: First Prize Goes to Natera (NASDAQ:NTRA)Let’s dig into the relative performance of Natera (
NASDAQ:NTRA) and its peers as we unravel the now-completed Q1 immuno-oncology earnings season.
1 Volatile Stock to Own for Decades and 2 to Brush OffVolatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains.
This unpredictability can shake out even the most experienced investors.
Q1 Rundown: Regeneron (NASDAQ:REGN) Vs Other Immuno-Oncology StocksEarnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Regeneron (
NASDAQ:REGN) and its peers.
3 Reasons We Love Natera (NTRA)Natera has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 5% to $170 per share while the index has gained 1.1%.
A Look Back at Immuno-Oncology Stocks’ Q1 Earnings: Exact Sciences (NASDAQ:EXAS) Vs The Rest Of The PackAs the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno-oncology industry, including Exact Sciences (
NASDAQ:EXAS) and its peers.
NTRA Q1 Earnings Call: Growth in Oncology and Women's Health Drives Guidance IncreaseGenetic testing company Natera (
NASDAQ:NTRA). reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 36.5% year on year to $501.8 million. The company’s full-year revenue guidance of $1.98 billion at the midpoint came in 4% above analysts’ estimates. Its non-GAAP loss of $0.50 per share was 24.2% above analysts’ consensus estimates.
Natera Announces Medicare Coverage for Signatera™ Genome
Natera, Inc. (
NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its genome-based Signatera MRD assay is now covered by Medicare under LCD L38779.
SignateraTM Genome Clinical Performance Highlighted at ASCO 2025
Natera, Inc. (
NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced results from a large-scale pan-cancer study of its Signatera Genome assay, which was presented today, June 2nd, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
2 Cash-Heavy Stocks for Long-Term Investors and 1 to Be Wary OfCompanies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments.
Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.
3 Mid-Cap Stocks Worth Your AttentionLarge trillion-dollar companies are tightening their grip on the market, often by acquiring smaller rivals.
This trend will likely pick up with new regulatory leadership, but a few mid-sized businesses will continue prospering by anchoring themselves in unique market segments.
Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting
Natera, Inc. (
NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that data from more than 25 Signatera studies will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30 - June 3, 2025 in Chicago, IL.
Natera (NASDAQ:NTRA) Surprises With Strong Q1, Guides for Strong Full-Year SalesGenetic testing company Natera (
NASDAQ:NTRA). announced better-than-expected revenue in Q1 CY2025, with sales up 36.5% year on year to $501.8 million. The company’s full-year revenue guidance of $1.98 billion at the midpoint came in 3.1% above analysts’ estimates. Its GAAP loss of $0.50 per share was 21.4% above analysts’ consensus estimates.
Natera Reports First Quarter 2025 Financial Results
Natera, Inc. (
NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the first quarter ended March 31, 2025.
Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress
Natera, Inc. (
NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, will present multiple datasets in breast cancer together with its collaborators at the 2025 ESMO Breast Cancer Annual Congress in Munich, Germany, taking place from May 14-17, 2025.
Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows
Natera, Inc. (
NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the American Journal of Transplantation (AJT) published a new study1 evaluating the performance of Prospera Heart with DQS to detect allograft rejection.
What To Expect From Natera’s (NTRA) Q1 EarningsGenetic testing company Natera (
NASDAQ:NTRA). will be reporting earnings tomorrow after market hours. Here’s what you need to know.
